These different interventions may, in turn, affect systemic immune responses, including RA-related biomarkers such as anti-CCP antibodies, pro-inflammatory cytokines (e.g., IL-6, TNF-α), and CRP levels [70,71,72]. The gene discussed is IL6; the disease is rheumatoid arthritis.